NIM-1324 vs omilancor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: LANCL2 · full Ulcerative Colitis pipeline
NIM-1324
Developed by NImmune Biopharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
omilancor
Developed by NImmune Biopharma
NCT03861143 · Phase 2 · completed
The study was randomized, triple-blind, placebo-controlled, and included 198 participants, with clinical remission defined using clinical and endoscopic components of the modified Mayo Score. Remission rates favored BT-11 numerically, but statistical significance for the primary endpoint was not reported, so the result remains unclear.
Reported efficacy
Clinical Remission (Week 12): Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7% (unclear)
Result source: NCT03861143
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NIM-1324 | omilancor |
|---|---|---|
| Clinical remission (induction) | —Not reported | 31.8% vs 22.7%+9.1 vs placeboNCT038611431 other result
|
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- NIM-1324
- —Not reported
- omilancor
- 31.8% vs 22.7%+9.1 vs placeboNCT03861143
1 other result
- 30.3% vs 22.7% NCT03861143
Clinical remission (maintenance)
- NIM-1324
- —Not reported
- omilancor
- —Not reported
Clinical response (induction)
- NIM-1324
- —Not reported
- omilancor
- —Not reported
Endoscopic improvement (induction)
- NIM-1324
- —Not reported
- omilancor
- —Not reported
Corticosteroid-free remission (maintenance)
- NIM-1324
- —Not reported
- omilancor
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NIM-1324: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. NIM-1324: 0 of 4 rows · omilancor: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | omilancor |
|---|---|
| Dropout rate | 10.6%880 mga NCT03861143 · Phase 2 · monotherapy show 1 more result6.1%440 mg NCT03861143 · Phase 2 · monotherapy |
| Discontinued due to AEs | —880 mga NCT03861143 · Phase 2 · monotherapy show 1 more result—440 mg NCT03861143 · Phase 2 · monotherapy |
| Serious AEs | 4.5%880 mga NCT03861143 · Phase 2 · monotherapy show 1 more result3%440 mg NCT03861143 · Phase 2 · monotherapy |
| Most frequent reported AEs | 880 mga colitis ulcerative 12.1% (placebo 9.1%) other 12.1% (placebo 19.7%) anemia 7.6% (placebo 0%) NCT03861143 · Phase 2 · monotherapy show 1 more result440 mg colitis ulcerative 15.2% (placebo 9.1%) other 9.1% (placebo 19.7%) diarrhea 4.5% (placebo 1.5%) NCT03861143 · Phase 2 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
omilancor
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NIM-1324's landscape · omilancor's landscape